We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

37 hedge funds and large institutions have $30.4M invested in Inozyme Pharma in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 10

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 39 → 37 (-2)

6.91% less ownership

Funds ownership: 78.57% → 71.66% (-6.9%)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

64% less capital invested

Capital invested by funds: $84.6M → $30.4M (-$54.2M)

Holders
37
Holders Change
-2
Holders Change %
-5.13%
% of All Funds
0.59%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
11
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$880K
2
AAA
Affinity Asset Advisors
New York
+$874K
3
SFM
Sphera Funds Management
Israel
+$786K
4
RSCM
Rock Springs Capital Management
Maryland
+$487K
5
CA
CHI Advisors
New York
+$365K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$5.6M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$3.81M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.63M
4
MB
MPM BioImpact
Massachusetts
-$753K
5
UOC
UBS O'Connor
Illinois
-$444K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$3.84M – – –
DTC
2
Deep Track Capital
Connecticut
$3.41M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$3.26M +$880K +503,466 +19%
RSCM
4
Rock Springs Capital Management
Maryland
$3.24M +$487K +278,409 +10%
VA
5
VR Adviser
New York
$2.85M – – –
PBPIA
6
Pivotal bioVenture Partners Investment Advisor
California
$2.79M – – –
NMC
7
NEA Management Company
Maryland
$2.56M -$11.7K -6,690 -0.3%
CA
8
CHI Advisors
New York
$2.32M +$365K +208,599 +10%
SFM
9
Sphera Funds Management
Israel
$1.71M +$786K +450,000 +38%
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.41M +$977 +559 +0%
AAA
11
Affinity Asset Advisors
New York
$525K +$874K +500,000 New
BlackRock
12
BlackRock
New York
$448K -$3.86K -2,207 -0.5%
Millennium Management
13
Millennium Management
New York
$313K +$223K +127,752 +75%
LCM
14
Laurion Capital Management
New York
$285K – – –
Renaissance Technologies
15
Renaissance Technologies
New York
$272K +$181K +103,500 +67%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$244K -$977 -559 -0.2%
MB
17
MPM BioImpact
Massachusetts
$242K -$753K -430,644 -65%
OMC
18
Overbrook Management Corp
New York
$230K +$262K +150,000 +216%
BCM
19
Bridgeway Capital Management
Texas
$140K – – –
State Street
20
State Street
Massachusetts
$80.2K – – –
Northern Trust
21
Northern Trust
Illinois
$48.2K +$9.86K +5,639 +14%
State of Wisconsin Investment Board
22
State of Wisconsin Investment Board
Wisconsin
$39.6K -$19.4K -11,100 -23%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$21.3K – – –
PA
24
Parallel Advisors
California
$20.9K +$34.7K +19,867 New
Charles Schwab
25
Charles Schwab
California
$17.4K – – –
1
2

INZY Hedge Fund Activity: Q4 2022 in Review

37 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2022, worth a combined $30.4M — down 64% from $84.6M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of INZY and 6 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 11 added.

The largest buyer was Adage Capital Partners, adding an estimated $880K. The largest seller was Deerfield Management, exiting entirely with an estimated $5.6M sold.

  • 37 institutional investors held Inozyme Pharma (INZY) as of Q4 2022, down from 39 in Q3 2022.
  • Funds reported $30.4M of Inozyme Pharma stock for Q4 2022, down 64% quarter-over-quarter.
  • 6 funds opened new Inozyme Pharma positions in Q4 2022 and 8 closed out, a net change of -2 holders.
  • The largest Inozyme Pharma buyer in Q4 2022 was Adage Capital Partners, an estimated $880K added.
  • The largest Inozyme Pharma seller in Q4 2022 was Deerfield Management, an estimated $5.6M sold.

Based on aggregated 13F filings for Q4 2022.